Alicia Morgans, MD, MPH

Alicia Morgans, MD, MPH, is a Genitourinary Medical Oncologist and the Director of the Survivorship Program at Dana-Farber Cancer Institute.

Articles

Dr Morgans on the Influence of HRQOL Data on the Use of Darolutamide Plus ADT in mHSPC

July 9th 2025

Alicia Morgans, MD, MPH, discusses how PRO data from the ARANOTE trial could inform the selection of darolutamide plus ADT for patients with mHSPC.

Emerging Trials and the Future of Biomarker-Driven Therapy in Metastatic Castration-Sensitive Prostate Cancer

July 9th 2025

Panelists discuss how emerging trials like AMPLITUDE (PARP inhibitors for BRCA mutations), PSMA-ADDITION (radioligand therapy), and CAPITELLO (AKT inhibitors for PTEN deficiency) are moving the field toward increasingly complex, biomarker-driven treatment selection.

Choosing a Chemotherapy-Based Triplet Regimen in Metastatic Castration-Sensitive Prostate Cancer

July 9th 2025

Panelists discuss how the ARASENSE and PEACE-1 phase 3 trials demonstrated the efficacy of triplet therapy combining androgen deprivation therapy (ADT), docetaxel, and novel antiandrogens, while addressing the ongoing underutilization of intensified treatment approaches.

FDA Approval Insights: Darolutamide for Metastatic Castration-Sensitive Prostate Cancer: With Alicia Morgans, MD, MPH; and Neal Shore, MD, FACS

July 3rd 2025

Drs Morgans and Shore discuss the significance of the FDA approval of darolutamide plus ADT for metastatic castration-sensitive prostate cancer.

Patient Fitness and the Doublet vs Triplet Debate in Metastatic Castration-Sensitive Prostate Cancer

June 30th 2025

Panelists discuss how medical comorbidities, physiologic vs chronologic age, drug interactions, and performance status influence the choice between doublet and triplet therapy regimens.

Personalizing Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer

June 30th 2025

Panelists discuss how clinical factors, including disease characteristics (Gleason score, volume, metastatic sites), patient factors (performance status, comorbidities, symptoms), and emerging genomic biomarkers, guide treatment intensification decisions in metastatic castration-sensitive prostate cancer.

Dr Morgans on HRQOL Outcomes With Darolutamide Plus ADT in mHSPC

June 23rd 2025

Alicia Morgans, MD, MPH, discusses health-related quality of life outcomes with darolutamide plus ADT in patients with mHSPC.

The Expanding Role of AR Inhibition in mHSPC Management: With Alicia Morgans, MD, MPH

June 16th 2025

Alicia Morgans, MD, MPH, details the evolving role of AR inhibitors in the mHSPC setting, including the recent expanded approval for darolutamide for this population.

Dr Morgans on Standardizing the Management of Bone/Cardiac Health With Systemic Therapy in Prostate Cancer

March 27th 2025

Alicia Morgans, MD, MPH, discusses the importance of managing bone and cardiac health in patients with prostate cancer receiving systemic therapy.

Dr Morgans on PSA Doubling Time and Treatment Decisions in Biochemically Recurrent nmHSPC

March 25th 2025

Alicia Morgans, MD, MPH, discusses how a lack of PSA doubling time documentation may lead to undertreatment in high-risk BCR prostate cancer.

Dr Morgans on Recent Adjustments to Medicare Part D to Improve Treatment Access in Prostate Cancer

September 24th 2024

Alicia Morgans, MD, MPH, discusses recent adjustments to Medicare Part D rules, emphasizing their positive impact on out-of-pocket costs for patients with prostate cancer.

Dr Morgans on Previously Reported Data From the ARAMIS Trial in nmCRPC

September 18th 2024

Alicia Morgans, MD, MPH, discusses prior data and follow-up analysis of the ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

Dr Morgans on Considerations for Treating nmCRPC in the Community Setting

August 22nd 2024

Alicia Morgans, MD, MPH, discusses considerations for oncologists treating patients with nonmetastatic castration-resistant prostate cancer in the community setting.

Dr Morgans on the Relationship Between PSA Levels and Radiographic Progression in nmCRPC

July 25th 2024

Alicia Morgans, MD, MPH, discusses key data from the follow-up analysis of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

Dr Morgans on the Importance of Detecting Radiographic Progression in nmCRPC

July 19th 2024

Alicia Morgans, MD, MPH, discusses data from the ARAMIS trial showing the association between PSA levels and radiological progression in nmCRPC.

Prostate Cancer Management: Future Directions in Care

May 25th 2022

Closing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.

Results of the VISION Trial and Real-World Use of 177Lu-PSMA-617 in mCRPC

May 25th 2022

Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Addressing Bone and Visceral Metastases in Metastatic CRPC

May 18th 2022

A broader perspective on the management of bone and visceral metastases in metastatic CRPC given the current treatment landscape.

Role of 177Lu-PSMA-617 in mCRPC and Bone Metastases

May 18th 2022

Shifting their focus to 177Lu-PSMA-617 in metastatic CRPC, expert panelists consider its role in sequencing therapy and managing bone metastases.

Selecting Among Novel Imaging Options in Metastatic CRPC

May 11th 2022

A brief discussion on how to select and apply novel imaging strategies in patients with metastatic castration-resistant prostate cancer.